Overall rank by patents
#48,029
of 49,997 tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61L (Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES;).
The verdict
According to USPTO PatentsView, Julius ranks #48,029 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 3 technology areas.
USPTO PatentsView assignee plate
Corpus R48029 · Foreign Corporation #48,029 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-LOW · CLAIMS-SPARSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
Nearest grant-volume peer: JTI Biomed Corp. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Julius Samann · this assignee
16 score
3D Lighting… · lowest
7 score
What this shows Julius's Innovation Score is 15.6/100 (3rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Julius Samann Ltd. is a focused PatentsView assignee: 3 CPC subclasses with 20% of grants classified under A61L (Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES;). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2016. By volume, Julius sits between JTI Biomed Corp. and Juvalips, LLC.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
JTI Biomed Corp.
5 patents
Jubilant Biosys Limited
5 patents
Juggernaut Tactical, Inc.
5 patents
Juice Technology AG
5 patents
Jumpcode Genomics, Inc.
5 patents
Jurop S.P.A.
5 patents
Justeq, LLC
5 patents
Juvalips, LLC
5 patents
Julius Samann Ltd.
5 patents
What this shows Julius holds 5 patents at rank #47,978, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #47,978 in granted patent volume.
Other assignees with the most granted patents in Julius's primary technology class.
Julius's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
16 3rd percentile higher than 3% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 60.0% |
| 2016 | 1 | 20.0% |
| 2018 | 1 | 20.0% |
Top 3 of 3 technology areas
Overall rank by patents
#48,029
of 49,997 tracked assignees
15.6 out of 100
What to do with this data
Julius Samann Ltd.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.